Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (1021-1030 of 1,060) with videos related to

Pageof 106
Sort By:
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
Pediatrics|December 26, 2015
Outbreaks of Salmonellosis From Small TurtlesMaroya Spalding Walters, Latoya Simmons, Tara C Anderson, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
European Journal of Heart Failure|August 17, 2018
Heart failure with preserved ejection fraction in AsiaJasper Tromp, Tiew-Hwa Teng, Wan Ting Tay, et al.
Circulation. Heart Failure|May 29, 2015
Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart FailureRaya E Kheirbek, Ross D Fletcher, Marie A Bakitas, et al.
Micropublication Biology|November 28, 2024
Three Cluster O mycobacteriophages isolated in Philadelphia, PAAlexander DiGiacomo, Nicole Bowen, Thientrinh Nguyen, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 106

Showing results (1021-1030 of 1,060) with videos related to

Sort By:
Pageof 106
JACC. Heart Failure|June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary TrialsMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
Pediatrics|December 26, 2015
Outbreaks of Salmonellosis From Small TurtlesMaroya Spalding Walters, Latoya Simmons, Tara C Anderson, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
European Journal of Heart Failure|August 17, 2018
Heart failure with preserved ejection fraction in AsiaJasper Tromp, Tiew-Hwa Teng, Wan Ting Tay, et al.
Circulation. Heart Failure|May 29, 2015
Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart FailureRaya E Kheirbek, Ross D Fletcher, Marie A Bakitas, et al.
Micropublication Biology|November 28, 2024
Three Cluster O mycobacteriophages isolated in Philadelphia, PAAlexander DiGiacomo, Nicole Bowen, Thientrinh Nguyen, et al.
Circulation|November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 106